Tiden er kommet for å gå inn i PCIB igjen
No-deal med AZ har gruset aksjekursen på tross av at FimaNac (der AZ samarbeidet foregikk) er den divisjonen som er lengst fra markedet og er tillagt minst verdi.
Bruddet gjorde at alle kortsiktige forsvant i tillegg til at mange mistet troen på leveringsteknologien.
Men den virker fortsatt. Det vet vi fra resultatene så langt i GGK (GalleGangKreft med over 2X overlevelsestid) og fra resultatene fra samarbeidet med AZ. (200X forbedret levering) og fra FimaVacc (8X forbedret T-celle respond)
Pandemien går mot slutten, rekrutteringen tar seg opp.
1 - Release (FimaChem) nærmer seg godkjenning (ca 2 år)
2 - Det kommer en partneravtale i Asia når som helst
3 - FimaVacc skal i følge Per kunne komme med resultater fra fase2 i 2022. Altså må fase2 starte meget snart. Antagelig med partner ettersom PCIB ikke har egenutviklet vaksine
4 - eTheRNA har forsket i FimaNac like lenge som AZ hadde da de fikk et ultimatum fra PCIB. Ettersom de fortsatt forsker (ikke ble utrensket sammen med bl.a Biontech) må de ha meget gode resultater å vise til. Det betyr at det trolig vil komme en ny fase (avtale) i samarbeidet.
5 - mRNA har fått ny oppmerksomhet gjennom pandemien. PCIB er best på presisjonslevering og "naked delivery". CRISPR + PCIB = fremtidens medisin
KONKLUSJON
Det smeller når som helst.
You have been warned :-)
For senere dokumentasjon : Kurs akkurat nå = 26,20
Bruddet gjorde at alle kortsiktige forsvant i tillegg til at mange mistet troen på leveringsteknologien.
Men den virker fortsatt. Det vet vi fra resultatene så langt i GGK (GalleGangKreft med over 2X overlevelsestid) og fra resultatene fra samarbeidet med AZ. (200X forbedret levering) og fra FimaVacc (8X forbedret T-celle respond)
Pandemien går mot slutten, rekrutteringen tar seg opp.
1 - Release (FimaChem) nærmer seg godkjenning (ca 2 år)
2 - Det kommer en partneravtale i Asia når som helst
3 - FimaVacc skal i følge Per kunne komme med resultater fra fase2 i 2022. Altså må fase2 starte meget snart. Antagelig med partner ettersom PCIB ikke har egenutviklet vaksine
4 - eTheRNA har forsket i FimaNac like lenge som AZ hadde da de fikk et ultimatum fra PCIB. Ettersom de fortsatt forsker (ikke ble utrensket sammen med bl.a Biontech) må de ha meget gode resultater å vise til. Det betyr at det trolig vil komme en ny fase (avtale) i samarbeidet.
5 - mRNA har fått ny oppmerksomhet gjennom pandemien. PCIB er best på presisjonslevering og "naked delivery". CRISPR + PCIB = fremtidens medisin
KONKLUSJON
Det smeller når som helst.
You have been warned :-)
For senere dokumentasjon : Kurs akkurat nå = 26,20
Redigert 10.03.2021 kl 11:30
Du må logge inn for å svare
teaa
10.03.2021 kl 15:04
11339
Risikoen er at PCIB finner det nødvendig med en emisjon.
Dette er sjelden kursdrivende..
Dette er sjelden kursdrivende..
Scoopfinder
10.03.2021 kl 15:14
11340
De har 190 mill på konto og brenner 20 mill i kvartalet.
Dessuten kan det komme avtaler med penger.
Tenk sjæl, så gjør vi opp status mot slutten av året.
Jeg skrev dagens kurs i trådstarten, så får vi se :-)
Dessuten kan det komme avtaler med penger.
Tenk sjæl, så gjør vi opp status mot slutten av året.
Jeg skrev dagens kurs i trådstarten, så får vi se :-)
Jensemand
10.03.2021 kl 15:25
11377
Scoopfinder - hvis PCIB ikke har svindlet med resultaterne, så har du nok rett
Scoopfinder
10.03.2021 kl 15:33
11367
Ja, det er utrolige resultater.
Noen av dem er det AZ som står for - bl.a sammenlignet levering av mRNA med Amphinex mot lipider.
De brukte mus med 2 svulster - PCI på den ene svulsten og lipider på den andre (i samme musa). resultatet ble 200X bedre i PCI svulsten.
Det er tvilsomt om PCIB har muldvarper i AZ som jukser med tallene :-)
Noen av dem er det AZ som står for - bl.a sammenlignet levering av mRNA med Amphinex mot lipider.
De brukte mus med 2 svulster - PCI på den ene svulsten og lipider på den andre (i samme musa). resultatet ble 200X bedre i PCI svulsten.
Det er tvilsomt om PCIB har muldvarper i AZ som jukser med tallene :-)
sokaratest
10.03.2021 kl 15:34
11356
Pcib har 4 ess på hånden som alle kan gjøre Aksjen årets børsrakett
sokaratest
10.03.2021 kl 15:58
11311
Podkast ( radforsk) behandler Pcib og gir gode svar på utvikling og muligheter
Kan tenke meg at PciB sitt Release studium er satt tilbake med minst et halvår eller bort i mot ett år
At de har valgt å ikke melde ytterligere forsinkelser er vel fordi de håper på å kompensere for dette ved raskere innrullering
Men dette har de neppe full kontroll på
At PW ble overrasket over AZ sin beslutning var en tankevekker som ikke så lett blir glemt
Når en leser innlegg om PciB på diverse fora er spekulasjoner og teorier det mest fremtredende-slik det alltid har vært i denne aksjen
At de har valgt å ikke melde ytterligere forsinkelser er vel fordi de håper på å kompensere for dette ved raskere innrullering
Men dette har de neppe full kontroll på
At PW ble overrasket over AZ sin beslutning var en tankevekker som ikke så lett blir glemt
Når en leser innlegg om PciB på diverse fora er spekulasjoner og teorier det mest fremtredende-slik det alltid har vært i denne aksjen
Redigert 10.03.2021 kl 19:54
Du må logge inn for å svare
Scoopfinder
10.03.2021 kl 21:39
11451
Merida, takk for at du viser at jeg hadde rett i trådstarten :
« Bruddet gjorde at alle kortsiktige forsvant i tillegg til at mange mistet troen på leveringsteknologien.»
Så får vi se til jul ☺️
« Bruddet gjorde at alle kortsiktige forsvant i tillegg til at mange mistet troen på leveringsteknologien.»
Så får vi se til jul ☺️
Bare hyggelig Scoop
Du er vel den eneste som ikke har skjelt meg ut for min noe kritiske vinkling til denne aksjen 😊
Du er vel den eneste som ikke har skjelt meg ut for min noe kritiske vinkling til denne aksjen 😊
Scoopfinder
11.03.2021 kl 16:21
11001
Hvorfor skulle jeg skjelle deg ut ?????
Jo flere skeptikere jo bedre. Det betyr større oppside når det kommer nyheter som får dere til å endre mening :-)
Jo flere skeptikere jo bedre. Det betyr større oppside når det kommer nyheter som får dere til å endre mening :-)
Spør ikke meg. Spør heller de som har gjorde det ;)
Newsman
21.03.2021 kl 21:46
9595
Denne aksjen kommer til å overraske mange når vi får første positive melding. På så lav kurs vi har i dag, vil den stige mye. Har tro på at Asia partner snart tikker inn. Som jeg har sagt før, denne aksjen vil gjøre oss veldig velstående. Det vil bare ta noe lenger tid enn vi først trodde. :)
Ebit
21.03.2021 kl 21:55
9569
Har også et håp om at aksjen vil overraske.
Men det hjelper lite bare å håpe.
Synes vi har vært på overtid i lengste laget, men, troen på en kortsiktig lottogevinst, er vel heller i det håpefulle enn det reelle.
Er litt oppgitt over nyhetstørken fra de høye herrer
Men det hjelper lite bare å håpe.
Synes vi har vært på overtid i lengste laget, men, troen på en kortsiktig lottogevinst, er vel heller i det håpefulle enn det reelle.
Er litt oppgitt over nyhetstørken fra de høye herrer
sokaratest
22.03.2021 kl 09:12
9375
Pcib kommer til å overraske stort - mye på gang.... AZ kan snart være på døren igjen
Newsman
22.03.2021 kl 11:51
9288
Det har vært diskutert en del om AZ skulle komme tilbake og jeg tror mange bare vil legge dette dødt, men det er sagt at de ikke ville inngå en avtale i det tidsrommet som ble avtalt. De hadde nok mange andre viktige prioriteringer i fjor. Jeg tar det heller som overraskelse om de gjør. Vi har så mye annet spennede å se fram til nå. Vi som leser mye på ulike forum må huske hva PW har sagt, hør heller på meg enn på ulike forum og jeg tolker dette som et positivt og selvsikkert utsagn. Hadde de ikke hatt så mye på gang håper jeg og jeg at han ville vært litt mer forsiktig. Reprising kommer!
Redigert 22.03.2021 kl 11:52
Du må logge inn for å svare
bravi
24.03.2021 kl 21:55
8944
Basert på historikken har man god tid før inngang i denne aksjen. Fra høsten 2018, etter emisjonen på 30 kr, tok det omtrent 1 år før kursen greide å etablere seg over 30. Da lå kursen omkring 26 i ett helt år, akkurat slik den har vært i de siste måneder. Hva skjer hvis det blir en emisjon på disse nivåene, la oss si emisjonskurs på 16-17 kr, da kan kursen historisk bli liggende mellom 10 og 15 i ett helt år. For selskapet og de ansatte er det knekkende likegyldig så lenge de får godt betalt og kan surre og tulle med jobbene sine uten at de leverer noe som helst. De får jo betalt uansett.
dalglish
24.03.2021 kl 23:47
8883
Et klassisk Bravi-innlegg der, altså :-) Jeg tenker at PCIB-aksjen minner meg litt om NANO for noen måneder siden. Den store majoriteten av optimister har blitt pessimister, alt er bare grått, trist og kjedelig. Så, plutselig kommer meldingen som forteller at ledelsen har visst ikke bare sittet foran PCen og tvinnet tommeltotter allikevel.
fabian2
31.05.2021 kl 11:34
8076
Kl 11.16 - USA
Redigert 31.05.2021 kl 11:35
Du må logge inn for å svare
heilo888
31.05.2021 kl 12:36
7937
Dette har potensiale til å bli gigantisk!
En kombivaksine med FimaVacc og CPI mot flere typer kreft!
Den som nå ikke skjønner sin kjøpsmulighet i PCIB vil aldri gjøre det!
https://finansavisen.no/nyheter/helse/2021/05/31/7681727/pci-biotech-far-patent-i-usa
PCI Biotech: US patent for the vaccine technology (fimaVacc) in combination with checkpoint inhibitors
Oslo (Norway), 31 May 2021 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announces that the U.S. Patent and Trademark
Office (USPTO) has informed the company that a new US patent will be granted
early June 2021. The US patent covers the use of fimaVacc in combination with
immune checkpoint inhibitors (ICIs).
The use of ICIs has revolutionised cancer immunotherapy, as this class of drugs
may induce long-lasting effects in those patients responding to treatment.
Unfortunately, most patients do not respond to ICI therapy and different
treatment combination strategies are explored with the aim to increase the
number of patients responding. Combining ICIs with therapeutic cancer vaccines
that induce relevant immune responses against the tumour cells is regarded as
one of the most promising strategies. The patent that soon will be granted in
the US covers the use of PCI Biotech's fimaVacc vaccination technology in
combination with important classes of ICIs and an important type of
immunological adjuvants (a class of so-called Toll like receptor agonists).
"Increasing the response rates to ICI's is one of the pharma industry's main
priorities in cancer and therapeutic cancer vaccination is a rational approach
to this aim. The fimaVacc technology has delivered encouraging immune responses
in early phase clinical trials and this US patent provides relevant intellectual
property for the further development of this technology." said Dr. Per Walday,
CEO of PCI Biotech.
As part of PCI Biotech's strategy for applying the PCI technology for
therapeutic cancer vaccines, several global patent applications were filed in
2013-2016. Today's announced US patent secure protection until 2036 and this
patent application is still pending in Europe and key Asian markets.
About fimaVacc
This novel vaccine technology applies a unique mode of action, triggered
endosomal release of antigens or antigen-encoding nucleic acids, to enhance
immune responses essential for therapeutic cancer vaccines as well as for
several types of vaccines against viral and parasitic infections. fimaVacc works
in synergy with several other state-of-the-art vaccination technologies, and is
especially effective in combination with some types of TLR agonists. The
fimaVacc programme aims to enhance the cellular immune responses that are
important for the therapeutic and prophylactic effect of vaccines, and the
fimaVacc technology has proven excellent preclinical efficacy with protein- and
peptide-based vaccines. The technology has shown particularly strong CD8 T-cell
immune responses, which are important for therapeutic vaccination, as well as
enhanced helper (CD4) T-cell and antibody responses.
PCI Biotech successfully translated the vaccination technology into humans
through a Phase I study in healthy volunteers that was completed in May 2019.
The study covered more than 90 subjects and established the tolerability of
fimaVacc across a wide range of doses. The immune results provided proof-of-
concept and demonstrates fimaVacc's potential to enhance overall T-cell
responses, by demonstrating improvement of the immunogenicity of vaccines in
healthy volunteers.
The results from the successful Phase I proof of concept study for the fimaVacc
technology were recently published in Frontiers in Immunology, a high impact
immunology journal. The article title is "Photochemical internalization enhanced
vaccination is safe, and gives promising cellular immune responses to an HPV
peptide-based vaccine in a phase I clinical study in healthy volunteers" and the
publication is available through this link:
https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/full
Effective induction of proper cellular immune responses will be critical to
realise the huge potential of therapeutic cancer vaccines, and is also important
for vaccination against some viral and parasitic infections. With present
technologies vaccines often fail to generate such responses, and especially
cytotoxic T-cell responses are often inappropriate. Insufficient delivery of
vaccine antigens to the appropriate presentation pathway in the immune cells may
be one of the main reasons for weak cytotoxic T-cell responses. The fimaVacc
technology has the potential to effectively enhance vaccine presentation through
these pathways.
En kombivaksine med FimaVacc og CPI mot flere typer kreft!
Den som nå ikke skjønner sin kjøpsmulighet i PCIB vil aldri gjøre det!
https://finansavisen.no/nyheter/helse/2021/05/31/7681727/pci-biotech-far-patent-i-usa
PCI Biotech: US patent for the vaccine technology (fimaVacc) in combination with checkpoint inhibitors
Oslo (Norway), 31 May 2021 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company, today announces that the U.S. Patent and Trademark
Office (USPTO) has informed the company that a new US patent will be granted
early June 2021. The US patent covers the use of fimaVacc in combination with
immune checkpoint inhibitors (ICIs).
The use of ICIs has revolutionised cancer immunotherapy, as this class of drugs
may induce long-lasting effects in those patients responding to treatment.
Unfortunately, most patients do not respond to ICI therapy and different
treatment combination strategies are explored with the aim to increase the
number of patients responding. Combining ICIs with therapeutic cancer vaccines
that induce relevant immune responses against the tumour cells is regarded as
one of the most promising strategies. The patent that soon will be granted in
the US covers the use of PCI Biotech's fimaVacc vaccination technology in
combination with important classes of ICIs and an important type of
immunological adjuvants (a class of so-called Toll like receptor agonists).
"Increasing the response rates to ICI's is one of the pharma industry's main
priorities in cancer and therapeutic cancer vaccination is a rational approach
to this aim. The fimaVacc technology has delivered encouraging immune responses
in early phase clinical trials and this US patent provides relevant intellectual
property for the further development of this technology." said Dr. Per Walday,
CEO of PCI Biotech.
As part of PCI Biotech's strategy for applying the PCI technology for
therapeutic cancer vaccines, several global patent applications were filed in
2013-2016. Today's announced US patent secure protection until 2036 and this
patent application is still pending in Europe and key Asian markets.
About fimaVacc
This novel vaccine technology applies a unique mode of action, triggered
endosomal release of antigens or antigen-encoding nucleic acids, to enhance
immune responses essential for therapeutic cancer vaccines as well as for
several types of vaccines against viral and parasitic infections. fimaVacc works
in synergy with several other state-of-the-art vaccination technologies, and is
especially effective in combination with some types of TLR agonists. The
fimaVacc programme aims to enhance the cellular immune responses that are
important for the therapeutic and prophylactic effect of vaccines, and the
fimaVacc technology has proven excellent preclinical efficacy with protein- and
peptide-based vaccines. The technology has shown particularly strong CD8 T-cell
immune responses, which are important for therapeutic vaccination, as well as
enhanced helper (CD4) T-cell and antibody responses.
PCI Biotech successfully translated the vaccination technology into humans
through a Phase I study in healthy volunteers that was completed in May 2019.
The study covered more than 90 subjects and established the tolerability of
fimaVacc across a wide range of doses. The immune results provided proof-of-
concept and demonstrates fimaVacc's potential to enhance overall T-cell
responses, by demonstrating improvement of the immunogenicity of vaccines in
healthy volunteers.
The results from the successful Phase I proof of concept study for the fimaVacc
technology were recently published in Frontiers in Immunology, a high impact
immunology journal. The article title is "Photochemical internalization enhanced
vaccination is safe, and gives promising cellular immune responses to an HPV
peptide-based vaccine in a phase I clinical study in healthy volunteers" and the
publication is available through this link:
https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/full
Effective induction of proper cellular immune responses will be critical to
realise the huge potential of therapeutic cancer vaccines, and is also important
for vaccination against some viral and parasitic infections. With present
technologies vaccines often fail to generate such responses, and especially
cytotoxic T-cell responses are often inappropriate. Insufficient delivery of
vaccine antigens to the appropriate presentation pathway in the immune cells may
be one of the main reasons for weak cytotoxic T-cell responses. The fimaVacc
technology has the potential to effectively enhance vaccine presentation through
these pathways.
EBAN
20.08.2021 kl 17:01
7419
Litt sig oppover her nå. Riktignok på små volum, men kan vi vente noe positivt ved q2?
bravi
20.08.2021 kl 21:54
7311
Hvem vet hva som kommer ved Q2, vanligvis er det ingenting, ihvertfall ikke noe kursdrivende. Dette er et evighets case.
ketle homeowner
20.08.2021 kl 22:00
7300
Ja, du ha nok rett i at det tar tid. Evihets case ... det får vi håpe er å overdrive - men det kan ta mange år
heilo888
20.08.2021 kl 23:52
7227
Noen revolusjonerende nyheter kommer ikke på Q2, men kan komme som som lyn fra klar himmel når man minst venter det. Og da som en børsmelding.
Men når det er sagt er faktisk PCIB et av de meget få selskaper som slipper mest info. som ikke er kjent fra før på sine kvartalspresentasjoner. Har fulgt alle deres presentasjoner i flere år, og spesielt ved spørsmålsrunden til slutt kommer det som regel en del ny og spennende informasjon.
Men føler meg rimelig sikker på at det blir sluppet en eller flere større nyheter nå i høst. Eksempelvis partnerskap i Asia, oppstart med en partner innen kreftvaksiner (FimaVacc) eller at pivotalstudiet innen gallegangskreft blir stoppet av etiske årsaker, og at alle pasientene, også kontrollgruppen, får PCIB sin behandling.
Ellers skjer det for tiden svært mye spennende hos deres samarbeidspartnere TheRNA og Olix i Sør Korea. Hos sistnevnte utvikles det i samarbeid med PCIB et middel mot skallethet som kan bli revolusjonerende og med et markedspotensiale på rundt 80 milliarder.
Dersom man tåler litt tålmodighet tror jeg at PCIB vil være et uhyre spennende selskap å følge i de kommende måneder og år.
Den som venter på noe godt venter ikke forgjeves da fortjenesten kan bli himmelhøy om de lykkes innen noen av deres satsningsområder.
Men når det er sagt er faktisk PCIB et av de meget få selskaper som slipper mest info. som ikke er kjent fra før på sine kvartalspresentasjoner. Har fulgt alle deres presentasjoner i flere år, og spesielt ved spørsmålsrunden til slutt kommer det som regel en del ny og spennende informasjon.
Men føler meg rimelig sikker på at det blir sluppet en eller flere større nyheter nå i høst. Eksempelvis partnerskap i Asia, oppstart med en partner innen kreftvaksiner (FimaVacc) eller at pivotalstudiet innen gallegangskreft blir stoppet av etiske årsaker, og at alle pasientene, også kontrollgruppen, får PCIB sin behandling.
Ellers skjer det for tiden svært mye spennende hos deres samarbeidspartnere TheRNA og Olix i Sør Korea. Hos sistnevnte utvikles det i samarbeid med PCIB et middel mot skallethet som kan bli revolusjonerende og med et markedspotensiale på rundt 80 milliarder.
Dersom man tåler litt tålmodighet tror jeg at PCIB vil være et uhyre spennende selskap å følge i de kommende måneder og år.
Den som venter på noe godt venter ikke forgjeves da fortjenesten kan bli himmelhøy om de lykkes innen noen av deres satsningsområder.
Redigert 21.08.2021 kl 00:38
Du må logge inn for å svare
KeesB
21.08.2021 kl 07:38
7173
Har du en link til det mht skallethet. Mener å ha lest at Olix var ferdig til studie start-up langt før Pcib og Olix traff hverandre. Så hvorfor linked til Pcib?
heilo888
21.08.2021 kl 12:23
7073
PCIB har inngått et samarbeid med Olix og ett av flere områder hvor de samarbeider er innen skallethet.
https://stop-hair-loss.eu/olix-inks-deal-to-test-hair-loss-rnai-therapeutic-with-pcis-delivery-technology-2021-05-11/
Tar med noen uttalelser fra PCIB sin CBO Robin og fra Olix:
Main comments by CBO:
“RNA may be very potent however someday troublesome to handle as a result of the usage of siRNA to inhibit goal genes has unintended effects in cells, such because the off-target impact, that makes it arduous to ship siRNA to particular cells or organs successfully,”
“Fimanac might optimize cytosolic supply of siRNA within the chosen focused organs or cells and keep away from the off-target impact.”
“We now have a twin goal with this settlement,” Robin defined. “Firstly exhibit that our expertise will be helpful with siRNA, and, secondly, develop a marketable remedy in collaboration with Olix.”
“We thought that our two applied sciences may very well be notably synergistic and efficient with this kind of molecule,”
“Moreover, a preclinical experimental program may very well be shortly arrange as a way to generate outcomes inside a reasonably quick time period.”
“We’re additionally in search of a focused collaborative method to take the Fimanac expertise into the clinic,”
Olix Head of R&D comments:
“We count on that combining our expertise with PCI’s expertise will improve the efficiency of our siRNA expertise,”
“As soon as the OLX-104C analysis research outcomes come out, we hope to broaden the applying space to our most cancers immunotherapy pipeline in addition to mRNA vaccines that we’re at the moment growing by means of our subsidiary, Mcurex Therapeutics Inc.”
Henviser også til følgende:
"Det er her PCI Biotech og Olix Pharma har samarbeid.
August 12, 2021 09:00 ET| Source: [OliX Pharmaceuticals]
GlobeNewswire News Room – 8 Dec 21 9
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and... 10
SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today...
Fra børsmelding PCIB om samarbeidet 5 mai 21
«
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical studies. The companies will evaluate results achieved from this research collaboration to explore the potential for further development and partnership. «
Og fra melding 12 august Olix i link over:
“We are pleased to receive this notice of allowance from the USPTO which validates our novel approach to treating male pattern baldness,” said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals. “OliX is building a leading pipeline of RNAi therapeutics for dermatological conditions. We look forward to advancing development of OLX104C as quickly as possible given the millions of people who are affected by hair loss.”
Da er der rask framgang i samarbeidet ser det ut til💪
Det var selveste Anders Høgset (og Einarsson) som antydet dette på Radium podkast ep 174, 27:46 Einarsson: «…, men også det at de (Olix pharma) jobber med , holdt på å si, hud og hår. Og det gjør jo hele belysningsprosessen så utrolig mye enklere da. Også tenkte jeg sånn med en gang, Alopecia areata som det heter, det er sånn hårtap, håret detter av i flekker, og hvis de skal jobbe med det, er det no sånn voldsomt stort marked da (tenkte jeg), også kikka jeg litt på talla, og det er jo det. Så…
https://stop-hair-loss.eu/olix-inks-deal-to-test-hair-loss-rnai-therapeutic-with-pcis-delivery-technology-2021-05-11/
Tar med noen uttalelser fra PCIB sin CBO Robin og fra Olix:
Main comments by CBO:
“RNA may be very potent however someday troublesome to handle as a result of the usage of siRNA to inhibit goal genes has unintended effects in cells, such because the off-target impact, that makes it arduous to ship siRNA to particular cells or organs successfully,”
“Fimanac might optimize cytosolic supply of siRNA within the chosen focused organs or cells and keep away from the off-target impact.”
“We now have a twin goal with this settlement,” Robin defined. “Firstly exhibit that our expertise will be helpful with siRNA, and, secondly, develop a marketable remedy in collaboration with Olix.”
“We thought that our two applied sciences may very well be notably synergistic and efficient with this kind of molecule,”
“Moreover, a preclinical experimental program may very well be shortly arrange as a way to generate outcomes inside a reasonably quick time period.”
“We’re additionally in search of a focused collaborative method to take the Fimanac expertise into the clinic,”
Olix Head of R&D comments:
“We count on that combining our expertise with PCI’s expertise will improve the efficiency of our siRNA expertise,”
“As soon as the OLX-104C analysis research outcomes come out, we hope to broaden the applying space to our most cancers immunotherapy pipeline in addition to mRNA vaccines that we’re at the moment growing by means of our subsidiary, Mcurex Therapeutics Inc.”
Henviser også til følgende:
"Det er her PCI Biotech og Olix Pharma har samarbeid.
August 12, 2021 09:00 ET| Source: [OliX Pharmaceuticals]
GlobeNewswire News Room – 8 Dec 21 9
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and... 10
SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today...
Fra børsmelding PCIB om samarbeidet 5 mai 21
«
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical studies. The companies will evaluate results achieved from this research collaboration to explore the potential for further development and partnership. «
Og fra melding 12 august Olix i link over:
“We are pleased to receive this notice of allowance from the USPTO which validates our novel approach to treating male pattern baldness,” said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals. “OliX is building a leading pipeline of RNAi therapeutics for dermatological conditions. We look forward to advancing development of OLX104C as quickly as possible given the millions of people who are affected by hair loss.”
Da er der rask framgang i samarbeidet ser det ut til💪
Det var selveste Anders Høgset (og Einarsson) som antydet dette på Radium podkast ep 174, 27:46 Einarsson: «…, men også det at de (Olix pharma) jobber med , holdt på å si, hud og hår. Og det gjør jo hele belysningsprosessen så utrolig mye enklere da. Også tenkte jeg sånn med en gang, Alopecia areata som det heter, det er sånn hårtap, håret detter av i flekker, og hvis de skal jobbe med det, er det no sånn voldsomt stort marked da (tenkte jeg), også kikka jeg litt på talla, og det er jo det. Så…
bravi
21.08.2021 kl 15:50
7020
Hvor sannsynlig er det at Pcib skal få til noe som gir kr i kassa med lakselus og hårtap når de ikke klarer det med sine hovedsatsninger Chem, Vacc og Nac ? At Einarsson kommer med positive kommentarer på podcast betyr lite, den plata spilles om igjen og om igjen. For Einarsson spiller det ingen rolle, han er fornøyd sålenge han klaret å lure småaksjonærer til å bli med på emisjoner, det er hele formålet med de podcastene.
heilo888
21.08.2021 kl 16:22
7002
Åpnet nå for en gangs skyld et innlegg av deg og kan konstatere at du fortsatt kun sprer depressiv møkk!
Spamming av verste sort! Få deg et liv "bravi"!
Spamming av verste sort! Få deg et liv "bravi"!
Redigert 21.08.2021 kl 16:24
Du må logge inn for å svare
Helio888
Hva om Bravi har rett?
Det har gaatt 13 aar, med emisjon etter emisjon, uten at PCIB har solgt noe som helst? Og PCIB har holdt aksjonaeren varme ved og sende ut rapporter om alt de mener PCI teknologien kan benyttes til. Men salget uteblir, ja vi snakker om 0 salg. For BP har snudd ryggen til PCIB, og hadde selgerne i PCIB levd paa provisjonsloenn, hadde de sultet ihjel for lenge siden;-)) Hva forteller dette oss?
Hva om Bravi har rett?
Det har gaatt 13 aar, med emisjon etter emisjon, uten at PCIB har solgt noe som helst? Og PCIB har holdt aksjonaeren varme ved og sende ut rapporter om alt de mener PCI teknologien kan benyttes til. Men salget uteblir, ja vi snakker om 0 salg. For BP har snudd ryggen til PCIB, og hadde selgerne i PCIB levd paa provisjonsloenn, hadde de sultet ihjel for lenge siden;-)) Hva forteller dette oss?
Redigert 30.08.2021 kl 11:02
Du må logge inn for å svare
SomSa
31.08.2021 kl 08:30
6280
Forsinkelse?
The implementation of the amended protocol and the opening of Asian sites provided increased screening and enrolment to RELEASE in Q1, but the activity declined significantly in Q2 with only three patients included. The expected timeline for the interim analysis for potential accelerated approval is revised to 2H 2023
*Recruitment in Q3 started stronger with four patients included in July and the company continues to focus on enrolment of patients into the RELEASE study, with the emphasis on regular trial management, including overall performance evaluation and site replacement
https://www.pcibiotech.no/news/pci-biotech-first-half-year-2021-interim-results
heilo888
31.08.2021 kl 09:53
6097
Oslo (Norway), 31 August 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year 2021 results. Please find enclosed the report and presentation.
Highlights
fimaChem
*The implementation of the amended protocol and the opening of Asian sites provided increased screening and enrolment to RELEASE in Q1, but the activity declined significantly in Q2 with only three patients included. The expected timeline for the interim analysis for potential accelerated approval is revised to 2H 2023
*Recruitment in Q3 started stronger with four patients included in July and the company continues to focus on enrolment of patients into the RELEASE study, with the emphasis on regular trial management, including overall performance evaluation and site replacement
*First US patient enrolled in the RELEASE study
*Orphan drug designation granted in South Korea
fimaVacc
*Successful Phase I vaccination proof of concept study published in the high impact immunology journal, Frontiers in Immunology, demonstrating that fimaVacc enhances the immune response to peptide- and protein-based vaccines in healthy volunteers
*US patent granted for the use of fimaVacc in combination with immune checkpoint inhibitors
fimaNAc
*Encouraging data on enhanced delivery of mRNA for various medical applications was presented at the UK based 12th Annual RNA Therapeutics Virtual Conference
*Established extensive research collaboration with the South Korean company OliX Pharmaceuticals, a leading developer of RNAi therapeutics
Corporate
*Significantly strengthening the organisation with three highly skilled individuals; an experienced operational leader for RELEASE, and two key employees within clinical science and business development focusing on fimaVacc and fimaNAc
Per Walday, CEO of PCI Biotech, comments: “The organisation has been focused on the implementation of all the initiatives to recoup delays to the RELEASE study inflicted by the Covid-19 pandemic. On the positive side, South Korea has contributed strongly to the recruitment in 2021. Asia is a region with higher prevalence of bile duct cancer and South Korea is a key market in this region. The granting of orphan drug designation for fimaporfin in South Korea was an important step in the development of fimaChem for bile duct cancer and a recognition of the therapeutic benefits we seek to bring to the patients. The pandemic situation is however still fluid in 2021 and we have seen fluctuating recruitment this year, which unfortunately means that we need to revise our estimated timelines. The situation is expected to improve as the vaccination rates increase going forward. We are fully focused on optimal study performance and progress, with attention to site performance and proactive management of study specific risks. The focused efforts needed for RELEASE during the pandemic has unfortunately reduced available resources for fimaVacc and fimaNAc. We have strong confidence in the commercial potential of all our programmes and have therefore strengthened the organisation significantly, with three highly skilled employees that will play key roles in driving the progress of all programmes. For fimaVacc, the US patent granted for the use in combination with immune checkpoint inhibitors (ICI’s) provides important intellectual property for the further development of this programme. Increasing the response rates to ICI's is a main priority in the pharma industry and therapeutic cancer vaccination is a rational approach to this aim, with well-suited characteristics of the fimaVacc technology. For fimaNAc, we were pleased to announce a broad and exciting collaboration with OliX Pharmaceuticals in South Korea, and we continue to pursue new and value-adding collaborative opportunities.“
***
An online presentation in English will be held today, Tuesday 31 August 2021, at 08.30am CEST (local time). The presentation can be followed as a live webcast, access through link https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210831_1 or the company’s website under “Investors – Reports and presentations – Webcasts”.
Q&A session
There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The presentation will also be presented through a teleconference, mainly facilitated for investors intending to ask questions verbally during the Q&A session.
Dial-in details for teleconference, mainly facilitated for verbal questions during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to the scheduled start time using the dial-in numbers below. A line mediator will provide information on how to ask questions.
Norway +47 2195 6342 / Sweden +46 4 0682 0620 / Denmark +45 7876 8490 / United Kingdom +44 20 3769 6819 / United States +1 646 787 0157. If your country is not listed, we recommend that you use the dial-in details for UK.
When prompted, provide the confirmation code or event title.
Confirmation Code: 436187
Event title: PCI Biotech Holding conference call Q2
The interim report and the presentation will also be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 31 August 2021.
For further information, please contact:
Ronny Skuggedal, CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Ronny Skuggedal, CFO, PCI Biotech Holding ASA, on 31 August 2021.
Highlights
fimaChem
*The implementation of the amended protocol and the opening of Asian sites provided increased screening and enrolment to RELEASE in Q1, but the activity declined significantly in Q2 with only three patients included. The expected timeline for the interim analysis for potential accelerated approval is revised to 2H 2023
*Recruitment in Q3 started stronger with four patients included in July and the company continues to focus on enrolment of patients into the RELEASE study, with the emphasis on regular trial management, including overall performance evaluation and site replacement
*First US patient enrolled in the RELEASE study
*Orphan drug designation granted in South Korea
fimaVacc
*Successful Phase I vaccination proof of concept study published in the high impact immunology journal, Frontiers in Immunology, demonstrating that fimaVacc enhances the immune response to peptide- and protein-based vaccines in healthy volunteers
*US patent granted for the use of fimaVacc in combination with immune checkpoint inhibitors
fimaNAc
*Encouraging data on enhanced delivery of mRNA for various medical applications was presented at the UK based 12th Annual RNA Therapeutics Virtual Conference
*Established extensive research collaboration with the South Korean company OliX Pharmaceuticals, a leading developer of RNAi therapeutics
Corporate
*Significantly strengthening the organisation with three highly skilled individuals; an experienced operational leader for RELEASE, and two key employees within clinical science and business development focusing on fimaVacc and fimaNAc
Per Walday, CEO of PCI Biotech, comments: “The organisation has been focused on the implementation of all the initiatives to recoup delays to the RELEASE study inflicted by the Covid-19 pandemic. On the positive side, South Korea has contributed strongly to the recruitment in 2021. Asia is a region with higher prevalence of bile duct cancer and South Korea is a key market in this region. The granting of orphan drug designation for fimaporfin in South Korea was an important step in the development of fimaChem for bile duct cancer and a recognition of the therapeutic benefits we seek to bring to the patients. The pandemic situation is however still fluid in 2021 and we have seen fluctuating recruitment this year, which unfortunately means that we need to revise our estimated timelines. The situation is expected to improve as the vaccination rates increase going forward. We are fully focused on optimal study performance and progress, with attention to site performance and proactive management of study specific risks. The focused efforts needed for RELEASE during the pandemic has unfortunately reduced available resources for fimaVacc and fimaNAc. We have strong confidence in the commercial potential of all our programmes and have therefore strengthened the organisation significantly, with three highly skilled employees that will play key roles in driving the progress of all programmes. For fimaVacc, the US patent granted for the use in combination with immune checkpoint inhibitors (ICI’s) provides important intellectual property for the further development of this programme. Increasing the response rates to ICI's is a main priority in the pharma industry and therapeutic cancer vaccination is a rational approach to this aim, with well-suited characteristics of the fimaVacc technology. For fimaNAc, we were pleased to announce a broad and exciting collaboration with OliX Pharmaceuticals in South Korea, and we continue to pursue new and value-adding collaborative opportunities.“
***
An online presentation in English will be held today, Tuesday 31 August 2021, at 08.30am CEST (local time). The presentation can be followed as a live webcast, access through link https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210831_1 or the company’s website under “Investors – Reports and presentations – Webcasts”.
Q&A session
There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The presentation will also be presented through a teleconference, mainly facilitated for investors intending to ask questions verbally during the Q&A session.
Dial-in details for teleconference, mainly facilitated for verbal questions during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to the scheduled start time using the dial-in numbers below. A line mediator will provide information on how to ask questions.
Norway +47 2195 6342 / Sweden +46 4 0682 0620 / Denmark +45 7876 8490 / United Kingdom +44 20 3769 6819 / United States +1 646 787 0157. If your country is not listed, we recommend that you use the dial-in details for UK.
When prompted, provide the confirmation code or event title.
Confirmation Code: 436187
Event title: PCI Biotech Holding conference call Q2
The interim report and the presentation will also be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 31 August 2021.
For further information, please contact:
Ronny Skuggedal, CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Ronny Skuggedal, CFO, PCI Biotech Holding ASA, on 31 August 2021.